MMIRF (MedMira) EBITDA Margin %: -1,333.33% (As of Jan. 2026)


What is MedMira EBITDA Margin %?

MedMira MMIRF +302.48% EBITDA Margin % is -1,333.33% as of Jan. 2026. The stock has 6 warning signs investors should review. Among 944 Biotechnology companies, MedMira ranks worse than 80.3% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. MedMira's EBITDA for the three months ended in Jan. 2026 was $-0.24 Mil. MedMira's Revenue for the three months ended in Jan. 2026 was $0.02 Mil. Therefore, MedMira's EBITDA margin for the quarter that ended in Jan. 2026 was -1,333.33%.

MedMira  (OTCPK:MMIRF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

MedMira EBITDA Margin % Related Terms

MedMira EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for MedMira's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedMira EBITDA Margin % Chart

MedMira Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.65 -112.09 -364.02 -516.94 -1,298.86

MedMira Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,266.67 -1,107.14 -1,237.84 -948.72 -1,333.33

MMIRF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, MedMira's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MedMira EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where MedMira's EBITDA Margin % falls into.


MedMira EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

MedMira's EBITDA Margin % for the fiscal year that ended in Jul. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Jul. 2025 )/Revenue (A: Jul. 2025 )
=-2.286/0.176
=-1,298.86 %

MedMira's EBITDA Margin % for the quarter that ended in Jan. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Jan. 2026 )/Revenue (Q: Jan. 2026 )
=-0.24/0.018
=-1,333.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -1,333.33% mean?
MedMira (MMIRF) has a EBITDA Margin % of -1,333.33% as of Jan. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MedMira and its competitors. According to the industry distribution chart, MedMira ranks #758 out of 944 companies in the Biotechnology industry, placing it in the top 80.3%.
Is MedMira's EBITDA Margin % too high?
MedMira's current EBITDA Margin % is -1,333.33%. Based on the distribution chart, MedMira ranks #758 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does MedMira's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, MedMira ranks #758 out of 944 companies for EBITDA Margin %. This places MedMira in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MedMira and its competitors. MedMira's current EBITDA Margin % is -1,333.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedMira stock overvalued right now?
MedMira (MMIRF) has a current EBITDA Margin % of -1,333.33%. The current EBITDA Margin % is -1,333.33%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For MedMira (MMIRF), the current EBITDA Margin % is -1,333.33% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MedMira Business Description

Other Exchanges MIR:Canada
Address 155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company engaged in the research, development, and manufacturing of rapid diagnostics and technologies. The company operates in one reportable operating segment, rapid diagnostic products and services. Its product line includes HIV, COVID-19, syphilis, Multiplex, Miriad RVF Toolkit, and H. pylori. The company generates revenue from North America, Europe, and other regions, with the majority generated from North America.